Warwick Medical School, University of Warwick, Warwick, UK.
Department of Obstetrics and Gynecology, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
Int J Gynaecol Obstet. 2023 Aug;162 Suppl 2:43-57. doi: 10.1002/ijgo.14947.
Just as the investigation of abnormal uterine bleeding (AUB) is approached systematically using the two FIGO systems for AUB in the reproductive years, treatment options can be considered similarly. Therapeutic options fall into two categories-medical and surgical-and while medical management is typically regarded as first-line therapy, there are several exceptions defined by the presenting cause or causes, mainly when infertility is a concurrent issue. In the early 1990s, up to 60% of women underwent a hysterectomy for the symptom of heavy menstrual bleeding (HMB), but this figure has decreased. The number of women undergoing a hysterectomy for benign disorders continues to decline, along with an increase in hysterectomies performed using minimally invasive techniques. Discussions about therapeutic options are tailored to the individual patient, and we include the risks and benefits of each option, including no management, to enable the patient to make an informed choice. The different types of treatment options and the factors affecting decision-making are considered in this article.
正如使用 FIGO 生殖年龄段异常子宫出血(AUB)两个系统系统地研究异常子宫出血(AUB)一样,也可以类似地考虑治疗选择。治疗选择分为两类——医学和手术——虽然通常认为医学管理是一线治疗,但也有几个例外情况,主要是当存在不孕等并发问题时。在 20 世纪 90 年代早期,多达 60%的因月经过多(HMB)症状的妇女接受了子宫切除术,但这一数字已经下降。因良性疾病接受子宫切除术的妇女数量持续下降,同时采用微创技术进行的子宫切除术数量增加。关于治疗选择的讨论是针对个体患者的,我们包括了每种选择的风险和益处,包括不进行管理,以使患者能够做出明智的选择。本文考虑了不同类型的治疗选择以及影响决策的因素。